SBIR/STTR Research Award

High-yield production of GDP-fucose for fucosylation of molecules

Award identifier 3ebbe82b36d883ede32a9807800ae16c5b168e4fd4f9ad5178a6427d8613c141Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,277,790

Program and phase

SBIR · Phase II

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ZUCHEM INC.
Proposal award date
2015-04-01
Contract end date
2017-12-31
UEI
LHZKXV13TLJ7
Solicitation number
PA14-071
Topic code
300

Research abstract

DESCRIPTION provided by applicant Fucosylation plays an important role in many cellular processes Fucosylated oligosaccharides in the cell are involved in many biochemical recognition processes microbial infections toxin entry and cancer cell metastasis These properties make fucosylated molecules valuable for pharmaceutical and drug discovery needs but current production methods are very expensive and impractical Most notably is the expense and difficulty in producing the activated sugar GDP fucose Our goal is to increase accessibility of GDP fucose and fucosylated molecules such as oligosaccharides so that the research community can better understand the role of these compounds in human health develop novel antimicrobial anti inflammatory and anti cancer agents and develop strains suitable for large scale production of various oligosaccharides and fucosylated molecules Current methods described to date for the production of GDP fucose using either chemoenzymatic synthesis or modified E coli and S cerevisiae strains all yield only small milligram quantities of material or are overly complicated and canandapos t be scaled Here we propose to develop an entirely new yeast based method for production of GDP fucose There are two main advantages to this this yeast based system First it uses an inducible promoter in the presence of glucose to overexpress two enzymes capable of converting a naturally abundant source of GDP mannose to GDP fucose Second it utilizes a nucleotide sugar transporter for the extracellular release of GDP Fucose The system also allows the possibility of using additional enzymes for in vivo synthesis of target molecules In Phase I we demonstrated the feasibility of using this approach by developing a yeast strain that can produce GDP mannose at high yields overexpressing the enzymes necessary to convert GDP mannose to GDP fucose and demonstrating the ability to produce GDP fucose at high yields We have also demonstrated the ability to transport GDP fucose out of the cell and have determined the initial conditions for fermentation In Phase II we will further engineer and optimize the production of GDP fucose and demonstrate its utility by testing the production of several important fucosylated molecules such as human milk oligosaccharides and fucosylated proteins from starting materials that are readily available to us Finally Phase III commercialization will involve selling GDP fucose licensing the system for use in a variety of applications and using the system to produce custom fucosylated oligosaccharides small molecules and proteins PUBLIC HEALTH RELEVANCE We propose to develop a yeast based system for the production of GDP fucose in vivo at large scale This technology will make this sugar nucleotide economically available for modification of natural sugars lipids proteins antibiotics antibodie and vaccines The proposed research has the potential to open up several multi billion dollar markets in anti infective and anticancer therapeutics as well as having application in the production of nutritional oligosaccharides

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

16 SBIR/STTR records share this UEI (2005–2018). Reported award amounts total $6,534,146. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation, Department of Energy

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.